Abbott Laboratories (NYSE:ABT) Position Boosted by Butensky & Cohen Financial Security Inc.

Butensky & Cohen Financial Security Inc. boosted its position in Abbott Laboratories (NYSE:ABTGet Rating) by 2.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 29,024 shares of the healthcare product maker’s stock after buying an additional 709 shares during the quarter. Butensky & Cohen Financial Security Inc.’s holdings in Abbott Laboratories were worth $3,187,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Insight Inv LLC bought a new position in Abbott Laboratories during the second quarter worth $26,000. EdgeRock Capital LLC bought a new position in Abbott Laboratories during the third quarter worth $29,000. Johnson Midwest Financial LLC lifted its stake in Abbott Laboratories by 28.7% during the third quarter. Johnson Midwest Financial LLC now owns 560 shares of the healthcare product maker’s stock worth $35,000 after purchasing an additional 125 shares during the last quarter. Newbridge Financial Services Group Inc. lifted its stake in Abbott Laboratories by 148.4% during the third quarter. Newbridge Financial Services Group Inc. now owns 477 shares of the healthcare product maker’s stock worth $46,000 after purchasing an additional 285 shares during the last quarter. Finally, Vienna Asset Management LLC bought a new position in Abbott Laboratories during the third quarter worth $51,000. Institutional investors and hedge funds own 72.93% of the company’s stock.

Insider Activity

In other news, SVP Julie L. Tyler sold 260 shares of the business’s stock in a transaction on Wednesday, February 22nd. The stock was sold at an average price of $103.24, for a total transaction of $26,842.40. Following the sale, the senior vice president now directly owns 40,896 shares of the company’s stock, valued at $4,222,103.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, SVP Julie L. Tyler sold 260 shares of the business’s stock in a transaction on Wednesday, February 22nd. The stock was sold at an average price of $103.24, for a total transaction of $26,842.40. Following the sale, the senior vice president now directly owns 40,896 shares of the company’s stock, valued at $4,222,103.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Andrea F. Wainer sold 679 shares of the business’s stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $100.70, for a total value of $68,375.30. Following the sale, the executive vice president now directly owns 70,427 shares in the company, valued at $7,091,998.90. The disclosure for this sale can be found here. Insiders sold a total of 1,971 shares of company stock worth $199,140 over the last 90 days. 0.52% of the stock is currently owned by company insiders.

Abbott Laboratories Trading Down 2.0 %

NYSE:ABT opened at $97.01 on Friday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.23 and a current ratio of 1.63. The stock has a market cap of $168.60 billion, a price-to-earnings ratio of 24.81, a PEG ratio of 4.42 and a beta of 0.68. The business has a fifty day moving average of $106.80 and a 200-day moving average of $104.86. Abbott Laboratories has a 1 year low of $93.25 and a 1 year high of $124.36.

Abbott Laboratories (NYSE:ABTGet Rating) last announced its quarterly earnings data on Wednesday, January 25th. The healthcare product maker reported $1.03 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.13. The business had revenue of $10.09 billion during the quarter, compared to analyst estimates of $9.69 billion. Abbott Laboratories had a return on equity of 26.09% and a net margin of 15.88%. The company’s revenue was down 12.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.32 earnings per share. Equities analysts predict that Abbott Laboratories will post 4.38 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, May 15th. Stockholders of record on Friday, April 14th will be issued a $0.51 dividend. The ex-dividend date is Thursday, April 13th. This represents a $2.04 annualized dividend and a dividend yield of 2.10%. Abbott Laboratories’s dividend payout ratio (DPR) is 52.17%.

Analysts Set New Price Targets

ABT has been the topic of several research analyst reports. StockNews.com began coverage on Abbott Laboratories in a research note on Thursday. They set a “buy” rating on the stock. Sanford C. Bernstein increased their target price on Abbott Laboratories from $125.00 to $132.00 and gave the stock an “outperform” rating in a research report on Thursday, January 26th. Morgan Stanley increased their target price on Abbott Laboratories from $117.00 to $133.00 and gave the stock an “overweight” rating in a research report on Friday, January 6th. Citigroup increased their target price on Abbott Laboratories from $114.00 to $125.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. Finally, Stifel Nicolaus increased their target price on Abbott Laboratories from $110.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday, January 26th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $124.67.

Abbott Laboratories Profile

(Get Rating)

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products.

Featured Articles

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABTGet Rating).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.